TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02000037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary care
Description: Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
Study: NCT00005774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early surfactant
Description: Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
Study: NCT01309516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex Intervention
Description: This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
Study: NCT02756871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online guided self-help intervention for perfectionism
Description: CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony
Study: NCT00005774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice
Description: Surfactant according to current center practice, only after initiation of mechanical ventilation.
Study: NCT01668537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LF formulation of IMVAMUNE®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FD formulation of IMVAMUNE®
Study: NCT03780725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study: NCT04046653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allin
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allin
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplement
Study: NCT00112853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study: NCT04073277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCF-N-treated needles
Description: The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Untreated needles
Description: he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
Study: NCT00774748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insuflon
Description: Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
Study: NCT04384874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: A 12 week multi-stage exercise rehabilitation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: A 12 week multi-stage exercise rehabilitation program
Study: NCT03331406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: 12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
Study: NCT01873885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Single IV (Intravenous) Infusion
Description: 0.9% Sodium Chloride - 30 minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Single IV (Intravenous) Infusion
Description: 0.9% Sodium Chloride - 30 minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Single IV (Intravenous) Infusion
Description: 0.9% Sodium Chloride - 30 minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Single IV Infusion Vasomera (PB1046)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Single IV Infusion Vasomera (PB1046)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Single IV Infusion Vasomera (PB1046)
Study: NCT01855906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gap balanced surgical technique
Description: Gap balanced surgical technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured resection
Description: Measured resection surgical technique
Study: NCT03462147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
Study: NCT03463447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Dynamometer
Description: Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydraulic dynamometer
Description: Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
Study: NCT02508207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Description: Tezacaftor/Ivacaftor FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tezacaftor/Ivacaftor matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor matching placebo
Study: NCT01181128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII (rFVIIIFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII (rFVIIIFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII (rFVIIIFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advate®
Study: NCT00662701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Ablation
Description: Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
Study: NCT02371252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic alendronate
Description: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
Study: NCT01158586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
Study: NCT03913910

Intervention type: PROCEDURE
Intervention: Lipogems
Description: Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
Study: NCT02685865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEM Stent
Description: Hot Axios Fully covered self-expandable metal stent - Boston Scientific

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: 7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
Study: NCT03528850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine evaluation
Description: Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
Study: NCT03879863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%) QID
Description: Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution QID
Description: Vehicle Ophthalmic Solution administered QID for twelve weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%) QID to BID
Description: Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution QID to BID
Description: Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Study: NCT03579901

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Description: Breast augmentation

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Description: Breast augmentation

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Description: Breast augmentation

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Description: Breast augmentation
Study: NCT03370146

Intervention type: BEHAVIORAL
Intervention: Mental training based on Motor Imagery
Description: Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
Study: NCT02648997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 240 mg
Description: 240 mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab - 1 mg/kg
Description: 1 mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 480 mg
Description: 480 mg once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 480 mg
Description: 480 mg once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 3 mg/kg
Description: 3 mg/kg every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam RT
Description: IMRT, 3D-CRT, or proton-beam radiation therapy
Study: NCT02944617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient-Fortified Probiotic Yogurt
Description: Receive Activia yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF-TKI
Description: Must be received as standard of care chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGF-TKI
Description: Must be received as standard of care chemotherapy
Study: NCT01045018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Study: NCT03496415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
Study: NCT04827394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal warming mattress
Description: Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile polyethylene wrap
Description: Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
Study: NCT06209983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: 1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: 1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters.
Study: NCT04499664

Intervention type: DEVICE
Intervention: Monitoring of the autonomic nervous system
Description: Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
Study: NCT03370146

Intervention type: BEHAVIORAL
Intervention: Cognitive training
Description: Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.

Intervention type: BEHAVIORAL
Intervention: Evaluation of gait abilities
Description: All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
Study: NCT04571021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-DEPT
Description: Implementation of the novel triage algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEPT
Description: Existing triage algorithm
Study: NCT03575585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment only
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment only
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment plus feedback report
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
Study: NCT03496415

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
Study: NCT00771875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Antithymocyte Globulin (RATG)
Description: All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
Study: NCT03370146

Intervention type: BEHAVIORAL
Intervention: Evaluation of gait abilities
Description: All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities

Intervention type: BEHAVIORAL
Intervention: Evaluation of gait abilities
Description: All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
Study: NCT01310738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimoniate of N-methylglucamine
Description: Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B deoxycholate
Description: 1mg/kg/d, I.V. for 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 3mg/kg/d, I.V. for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 10mg/kg/d, I.V. single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimoniate of N-methylglucamine
Description: 20mg/kg/d of pentavalent antimonial I.V. for 10 days
Study: NCT00765583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
Study: NCT02172118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1774 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1774 CL
Study: NCT02032628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
Study: NCT04773769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Made of Graviola Leaves
Description: Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment.
Study: NCT02344940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Description: patients will take toremifene 60 mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: patients will take tamoxifen 10 mg bid.
Study: NCT03066076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithyroid Drug
Description: Antithyroid drug

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Operation
Study: NCT02739646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI scan
Description: 7.0 Tesla functional MRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI scan
Description: 7.0 Tesla functional MRI scan
Study: NCT01601977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE
Description: Novel ventilation mode (Omnilab - AVAPS AE algorithm)